What this Trial Is About

Researchers are investigating the safety of maintaining low-dose acetylsalicylic acid (aspirin) treatment at or below 250 mg during extracorporeal lithotripsy (ECL) sessions for patients with kidney stones. Kidney stones are increasingly common due to lifestyle and dietary changes, affecting about 10% of the French population. ECL is a common non-invasive treatment used for kidney stones smaller than 20 mm, but it carries a risk of causing renal hematomas, which this study aims to evaluate specifically on a 15-day scan. The study is a prospective, single-arm trial involving patients who continue their low-dose aspirin during ECL without stopping the medication beforehand. Prior to the procedure, patients undergo imaging and blood tests, and during the ECL session, blood pressure and pain are monitored. After treatment, patients receive follow-up scans at 15 days to check for renal hematomas and assess stone clearance, along with blood tests and pain evaluations. A follow-up consultation occurs about three weeks after the procedure to review outcomes and any complications. Participants will be closely monitored through imaging, laboratory tests, pain assessments, and medical history reviews throughout the study period, which is estimated to last around 5 to 6 weeks per patient. The main outcome measured is the proportion of patients developing renal hematomas after ECL while on aspirin, along with secondary outcomes including treatment effectiveness, hematuria occurrence, pain, post-treatment complications, and renal function changes. The study aims to simplify patient management and reduce cardiovascular risks by avoiding aspirin interruption during lithotripsy.

Maintenance of an Antiaggregation by Acetylsalicylic Acid, While a Extracorporeal Lithotripsy Session on a Kidney Stone is Perfomed: Comparative Unicentric Prospective Study